QQQ   398.56 (+0.18%)
AAPL   175.61 (+2.59%)
MSFT   332.73 (-0.65%)
FB   330.84 (+2.49%)
GOOGL   2,948.52 (+0.11%)
AMZN   3,528.45 (+0.15%)
TSLA   1,060.43 (+0.83%)
NVDA   317.12 (-2.20%)
BABA   125.74 (+0.16%)
NIO   34.97 (+5.59%)
CGC   11.01 (+3.48%)
AMD   144.42 (-0.30%)
GE   98.34 (+0.81%)
MU   85.64 (-0.22%)
T   23.21 (+0.56%)
F   19.83 (-0.65%)
DIS   153.20 (+1.58%)
PFE   51.49 (-0.44%)
AMC   32.64 (+5.15%)
ACB   6.61 (+3.61%)
BA   210.41 (+0.76%)
QQQ   398.56 (+0.18%)
AAPL   175.61 (+2.59%)
MSFT   332.73 (-0.65%)
FB   330.84 (+2.49%)
GOOGL   2,948.52 (+0.11%)
AMZN   3,528.45 (+0.15%)
TSLA   1,060.43 (+0.83%)
NVDA   317.12 (-2.20%)
BABA   125.74 (+0.16%)
NIO   34.97 (+5.59%)
CGC   11.01 (+3.48%)
AMD   144.42 (-0.30%)
GE   98.34 (+0.81%)
MU   85.64 (-0.22%)
T   23.21 (+0.56%)
F   19.83 (-0.65%)
DIS   153.20 (+1.58%)
PFE   51.49 (-0.44%)
AMC   32.64 (+5.15%)
ACB   6.61 (+3.61%)
BA   210.41 (+0.76%)
QQQ   398.56 (+0.18%)
AAPL   175.61 (+2.59%)
MSFT   332.73 (-0.65%)
FB   330.84 (+2.49%)
GOOGL   2,948.52 (+0.11%)
AMZN   3,528.45 (+0.15%)
TSLA   1,060.43 (+0.83%)
NVDA   317.12 (-2.20%)
BABA   125.74 (+0.16%)
NIO   34.97 (+5.59%)
CGC   11.01 (+3.48%)
AMD   144.42 (-0.30%)
GE   98.34 (+0.81%)
MU   85.64 (-0.22%)
T   23.21 (+0.56%)
F   19.83 (-0.65%)
DIS   153.20 (+1.58%)
PFE   51.49 (-0.44%)
AMC   32.64 (+5.15%)
ACB   6.61 (+3.61%)
BA   210.41 (+0.76%)
QQQ   398.56 (+0.18%)
AAPL   175.61 (+2.59%)
MSFT   332.73 (-0.65%)
FB   330.84 (+2.49%)
GOOGL   2,948.52 (+0.11%)
AMZN   3,528.45 (+0.15%)
TSLA   1,060.43 (+0.83%)
NVDA   317.12 (-2.20%)
BABA   125.74 (+0.16%)
NIO   34.97 (+5.59%)
CGC   11.01 (+3.48%)
AMD   144.42 (-0.30%)
GE   98.34 (+0.81%)
MU   85.64 (-0.22%)
T   23.21 (+0.56%)
F   19.83 (-0.65%)
DIS   153.20 (+1.58%)
PFE   51.49 (-0.44%)
AMC   32.64 (+5.15%)
ACB   6.61 (+3.61%)
BA   210.41 (+0.76%)

Analyst Ratings and Price Targets (12/8/2021)

CompanyActionBrokerageAnalystCurrent PricePrice TargetRatingDetails
AAPL
Apple
Target Set byThe Goldman Sachs Group
cited Apple’s
$174.89
+2.2%
$142.00
ACAD
ACADIA Pharmaceuticals
Target Raised byThe Goldman Sachs Group
$21.76
+2.1%
$25.00 ➝ $28.00Neutral
AIP
Arteris
Reiterated byRosenblatt Securities
$24.86
-7.1%
$35.00Buy
ALLE
Allegion
Downgraded byBank of America
$132.00
+0.2%
$163.00 ➝ $142.00Buy ➝ Neutral
ALLT
Allot Communications
Initiated byNorthland Securities
$12.09
+8.8%
$23.00Outperform
AOSL
Alpha and Omega Semiconductor
Target Raised byB. Riley
$53.59
-1.5%
$57.00 ➝ $67.00Buy
APA
APA
Target Lowered byBarclays
$26.75
-0.5%
$27.00 ➝ $26.00Equal Weight
APLS
Apellis Pharmaceuticals
Initiated byWells Fargo & Company
$42.95
+3.7%
$84.00Overweight
ARBE
Arbe Robotics
Target Raised byCowen
$11.25
+1.2%
$12.00 ➝ $15.00Outperform
ARGX
argenx
Initiated byWells Fargo & Company
$304.45
+4.1%
$390.00Overweight
ARNA
Arena Pharmaceuticals
Initiated byWells Fargo & Company
$53.81
+2.2%
$71.00Overweight
ASND
Ascendis Pharma A/S
Initiated byWells Fargo & Company
$145.98
+2.1%
$176.00Overweight
ASX
ASE Technology
Downgraded byJPMorgan Chase & Co.
$7.74
-4.4%
Overweight ➝ Neutral
ATUS
Altice USA
Target Lowered byBenchmark
$16.06
-3.2%
$48.00 ➝ $30.00Buy ➝ Buy
AVAV
AeroVironment
Downgraded byCanaccord Genuity
Austin Moeller
$61.54
+6.1%
$140.00 ➝ $64.00Buy ➝ Hold
AVAV
AeroVironment
Target Lowered byRoyal Bank of Canada
$61.54
+6.1%
$95.00 ➝ $65.00Sector Perform ➝ Sector Perform
AVAV
AeroVironment
Target Lowered byRobert W. Baird
Peter Arment
$61.54
+6.1%
$120.00 ➝ $72.00Outperform ➝ Outperform
AWK
American Water Works
Target Raised byBarclays
$177.32
+0.5%
$174.00 ➝ $187.00Equal Weight ➝ Equal Weight
AWR
American States Water
Downgraded byBarclays
Eric Beaumont
$98.21
-0.5%
$87.00 ➝ $96.00Equal Weight ➝ Underweight
AZO
AutoZone
Target Raised byCitigroup
$1,977.82
-2.3%
$1,950.00 ➝ $2,332.00Buy ➝ Buy
AZO
AutoZone
Target Raised byWedbush
$1,977.82
-2.3%
$1,900.00 ➝ $2,250.00Outperform ➝ Outperform
AZO
AutoZone
Target Raised byJefferies Financial Group
$1,977.82
-2.3%
$1,900.00 ➝ $2,350.00Buy ➝ Buy
AZO
AutoZone
Target Raised byThe Goldman Sachs Group
$1,977.82
-2.3%
$1,779.00 ➝ $2,045.00Neutral
AZO
AutoZone
Target Raised byRaymond James
$1,977.82
-2.3%
$1,950.00 ➝ $2,200.00Outperform ➝ Outperform
AZO
AutoZone
Target Raised byMorgan Stanley
Simeon Gutman
$1,977.82
-2.3%
$1,710.00 ➝ $2,050.00Equal Weight
AZO
AutoZone
Target Raised byStephens
$1,977.82
-2.3%
$1,850.00 ➝ $2,210.00Overweight
BASE
Couchbase
Target Lowered byThe Goldman Sachs Group
$28.50
-3.6%
$49.00 ➝ $42.00Neutral
BASE
Couchbase
Target Lowered byOppenheimer
Ittai Kidron
$28.50
-3.6%
$50.00 ➝ $44.00Outperform
BASE
Couchbase
Target Lowered byBarclays
$28.50
-3.6%
$52.00 ➝ $41.00Overweight ➝ Overweight
BCE
BCE
Reiterated byBarclays
$51.90
-0.8%
C$60.00Hold
BDX
Becton, Dickinson and
Downgraded byPiper Sandler
$246.44
-1.6%
$285.00 ➝ $260.00Overweight ➝ Neutral
BGRY
Berkshire Grey
Initiated byBank of America
$5.37
+9.8%
$12.00Buy
BIGC
BigCommerce
Initiated byBank of America
$43.18
+4.7%
$66.00Buy
BLDR
Builders FirstSource
Target Raised byBarclays
$76.63
+0.8%
$90.00 ➝ $98.00Overweight ➝ Overweight
BLDR
Builders FirstSource
Target Raised byBMO Capital Markets
$76.63
+0.8%
$76.00 ➝ $92.00Outperform ➝ Outperform
BLDR
Builders FirstSource
Reiterated byBenchmark
$76.63
+0.8%
$100.00 ➝ $125.00Buy ➝ Buy
BNTX
BioNTech
Target Set byJefferies Financial Group
Tewari Akash
$295.83
-2.3%
$230.00
CABA
Cabaletta Bio
Initiated byWells Fargo & Company
$12.40
+5.4%
$17.00Overweight
CASY
Casey's General Stores
Target Lowered byRoyal Bank of Canada
Irene Nattel
$192.07
-4.5%
$246.00 ➝ $237.00Sector Perform
CDMO
Avid Bioservices
Target Raised byRoyal Bank of Canada
$28.95
+1.6%
$27.00 ➝ $32.00Outperform ➝ Outperform
CDMO
Avid Bioservices
Target Raised byCraig Hallum
$28.95
+1.6%
$29.00 ➝ $35.00Buy ➝ Buy
CLLS
Cellectis
Reiterated byJMP Securities
Silvan Tuerkcan
$9.35
+1.4%
$20.00Buy
CNM
Core & Main
Downgraded byCitigroup
$28.59
+0.2%
$32.00Buy ➝ Neutral
CNM
Core & Main
Target Raised byDeutsche Bank Aktiengesellschaft
$28.59
+0.2%
$33.00 ➝ $37.00Buy ➝ Buy
CNM
Core & Main
Target Raised byRobert W. Baird
$28.59
+0.2%
$32.00 ➝ $33.00Outperform ➝ Outperform
CNM
Core & Main
Target Raised byCredit Suisse Group
$28.59
+0.2%
$33.00 ➝ $40.00Outperform ➝ Outperform
CODX
Co-Diagnostics
Reiterated byHC Wainwright
Yi Chen
$8.92
+4.2%
$15.00Buy
COST
Costco Wholesale
Target Raised byMKM Partners
Bill Kirk
$528.34
-2.5%
$385.00 ➝ $498.00Neutral ➝ Neutral
CSL
Carlisle Companies
Target Raised byOppenheimer
Bryan Blair
$241.86
+0.0%
$255.00 ➝ $270.00Outperform ➝ Outperform
DARE
Daré Bioscience
Reiterated byHC Wainwright
Douglas Tsao
$2.12 $5.00Buy
ED
Consolidated Edison
Target Raised byCitigroup
$81.76
+0.2%
$77.00 ➝ $84.00Neutral ➝ Neutral
EDR
Endeavor Group
Reiterated byBarclays
30.53
-0.8%
Neutral ➝ Hold
ELAN
Elanco Animal Health
Reiterated byBarclays
$29.53
+1.9%
Neutral ➝ Hold
EMN
Eastman Chemical
Target Raised byWells Fargo & Company
$117.48
+3.4%
$130.00 ➝ $138.00Overweight ➝ Overweight
EMN
Eastman Chemical
Target Raised byKeyCorp
Aleksey Yefremov
$117.48
+3.4%
$119.00 ➝ $150.00Overweight ➝ Overweight
ESTC
Elastic
Upgraded byJPMorgan Chase & Co.
$130.15
+11.8%
$156.00Neutral ➝ Overweight
FTI
TechnipFMC
Upgraded byJefferies Financial Group
$6.62
+4.1%
$8.00 ➝ $9.00Hold ➝ Buy
GLBE
Global-e Online
Initiated byBank of America
$67.33
+3.7%
$80.00Buy
GLPI
Gaming and Leisure Properties
Target Raised byRaymond James
$47.27
+0.9%
$52.00 ➝ $54.00Strong-Buy
GPN
Global Payments
Target Lowered byRobert W. Baird
$130.28
+0.4%
$220.00 ➝ $205.00Outperform ➝ Outperform
HLI
Houlihan Lokey
Target Lowered byMorgan Stanley
Manan Gosalia
$104.41
-4.0%
$106.00 ➝ $97.00Underweight ➝ Underweight
HON
Honeywell International
Downgraded byBank of America
$205.00
-1.0%
$270.00 ➝ $245.00Buy ➝ Neutral
HP
Helmerich & Payne
Reiterated byBarclays
$24.56
+6.0%
Hold ➝ Neutral
HQY
HealthEquity
Target Lowered byDeutsche Bank Aktiengesellschaft
$44.30
+3.7%
$75.00 ➝ $52.00Buy ➝ Buy
HZNP
Horizon Therapeutics Public
Initiated byWells Fargo & Company
$104.25
+2.2%
$137.00Overweight
IDYA
IDEAYA Biosciences
Target Raised byRoth Capital
$23.32
+3.5%
$38.00 ➝ $42.00Buy ➝ Buy
IMVT
Immunovant
Initiated byWells Fargo & Company
$7.95
-0.5%
$9.00Equal Weight
INDT
INDUS Realty Trust
Initiated byAegis
$77.87
-0.6%
$89.00Buy
INTC
Intel
Target Set byJPMorgan Chase & Co.
Sur Harlan
$51.58
-1.9%
$64.00
INTC
Intel
Target Set byCredit Suisse Group
Pitzer John
$51.58
-1.9%
$80.00
IONS
Ionis Pharmaceuticals
Target Lowered bySVB Leerink
$32.27
+5.6%
$39.00 ➝ $36.00Market Perform
ITT
ITT
Upgraded byBank of America
$102.39
+1.0%
$112.00 ➝ $130.00Neutral ➝ Buy
JJSF
J & J Snack Foods
Initiated byBenchmark
$146.00
+2.1%
$171.00Buy
KEYS
Keysight Technologies
Initiated byMorgan Stanley
$202.20
-0.1%
$200.00Equal Weight
KHC
Kraft Heinz
Downgraded byGuggenheim
$33.37
-3.3%
$46.00 ➝ $33.00Buy ➝ Neutral
KZR
Kezar Life Sciences
Initiated byWells Fargo & Company
$14.80
+1.0%
$19.00Overweight
LANC
Lancaster Colony
Initiated byBenchmark
$153.82
+1.9%
$181.00Buy
LAZ
Lazard
Target Lowered byMorgan Stanley
Manan Gosalia
$44.70
-1.0%
$61.00 ➝ $55.00Overweight ➝ Overweight
LFUS
Littelfuse
Target Raised byCowen
$310.72
+0.1%
$305.00 ➝ $330.00Outperform ➝ Outperform
LULU
Lululemon Athletica
Target Lowered byCowen
John Kernan
$425.46
-2.2%
$520.00 ➝ $515.00Outperform ➝ Outperform
LUNG
Pulmonx
Upgraded byPiper Sandler
$35.97
+6.2%
$45.00Neutral ➝ Overweight
MBIO
Mustang Bio
Reiterated byBTIG Research
Justin Zelin
$2.13
+3.4%
$11.00Buy
MC
Moelis & Company
Target Lowered byMorgan Stanley
Manan Gosalia
$61.46
-2.0%
$75.00 ➝ $68.00Equal Weight ➝ Equal Weight
MDB
MongoDB
Target Raised byThe Goldman Sachs Group
Kash Rangan
$527.67
+5.6%
$475.00 ➝ $545.00Buy
MDXG
MiMedx Group
Reiterated byHC Wainwright
Swayampakula Ramakanth
$7.44
+1.1%
$8.50Buy
MEG
Montrose Environmental Group
Downgraded byBank of America
$70.80
+0.3%
$80.00Buy ➝ Neutral
MFA
MFA Financial
Upgraded byRaymond James
$4.68
+2.6%
$5.25Market Perform ➝ Outperform
MGNI
Magnite
Initiated byNeedham & Company LLC
Laura Martin
$18.64
+3.0%
$69.00Buy
MIME
Mimecast
Downgraded byRobert W. Baird
$79.26
-0.2%
Outperform ➝ Neutral
MORF
Morphic
Initiated byWells Fargo & Company
$49.02
-0.9%
$81.00Overweight
NATI
National Instruments
Initiated byMorgan Stanley
$43.70
+4.3%
$50.00Overweight
NBIX
Neurocrine Biosciences
Target Raised byOppenheimer
$84.32
+2.5%
$140.00 ➝ $154.00Outperform ➝ Outperform
NBIX
Neurocrine Biosciences
Target Raised byCitigroup
Neena Bitritto-Garg
$84.32
+2.5%
$127.00 ➝ $129.00Buy ➝ Buy
NBIX
Neurocrine Biosciences
Reiterated byHC Wainwright
Andrew Fein
$84.32
+2.5%
$139.00Buy
NEE
NextEra Energy
Target Raised byBMO Capital Markets
$90.45
+0.0%
$89.00 ➝ $98.00Outperform ➝ Outperform
NEM
Newmont
Target Lowered byBarclays
$56.25
-0.2%
$61.00 ➝ $59.00Equal Weight
NOTV
Inotiv
Reiterated byColliers Securities
Kyle Bauser
$54.85
+20.4%
$71.00Buy
NTR
Nutrien
Target Set byRoyal Bank of Canada
Wong Andrew
$70.94
+1.0%
$85.00
OCN
Ocwen Financial
Target Raised byB. Riley
M. Howlett
$36.69
+1.4%
$50.00 ➝ $56.00Buy ➝ Buy
OGI
OrganiGram
Target Raised byCantor Fitzgerald
$2.09
+4.3%
$5.50 ➝ $5.70Overweight
ON
ON Semiconductor
Target Raised byKeyCorp
John Vinh
$64.10
-2.1%
$65.00 ➝ $72.00Overweight ➝ Overweight
ONTO
Onto Innovation
Target Raised byBenchmark
Mark Miller
$97.79
-0.7%
$100.00 ➝ $110.00Buy ➝ Buy
PD
PagerDuty
Target Lowered byCraig Hallum
Chad Bennett
$37.62
+12.3%
$62.00 ➝ $52.00Buy ➝ Buy
PLAY
Dave & Buster's Entertainment
Target Lowered byPiper Sandler
$35.68
+7.8%
$53.00 ➝ $38.00Neutral ➝ Neutral
PLAY
Dave & Buster's Entertainment
Target Raised byTruist Securities
$35.68
+7.8%
$50.00 ➝ $56.00Buy
PRVA
Privia Health Group
Target Raised bySVB Leerink
W. Mayo
$23.18
+5.8%
$42.00 ➝ $43.00Outperform
RBCAA
Republic Bancorp
Downgraded byHovde Group
Bryce Rowe
$53.17
-1.6%
$57.00Outperform ➝ Market Perform
RBLX
Roblox
Initiated byKeyCorp
$123.65
+6.6%
Sector Weight ➝ Sector Weight
RJF
Raymond James
Target Raised byMorgan Stanley
Manan Gosalia
$98.70
-0.2%
$112.00 ➝ $122.00Overweight ➝ Overweight
RXDX
Prometheus Biosciences
Upgraded byOppenheimer
$33.38
+4.0%
$35.00 ➝ $50.00Market Perform ➝ Outperform
RXDX
Prometheus Biosciences
Target Raised bySVB Leerink
$33.38
+4.0%
$43.00 ➝ $47.00Outperform
RXDX
Prometheus Biosciences
Initiated byWells Fargo & Company
$33.38
+4.0%
$42.00Overweight
RXRX
Recursion Pharmaceuticals
Target Raised bySVB Leerink
$19.55
-5.6%
$30.00 ➝ $32.00Outperform
RYTM
Rhythm Pharmaceuticals
Initiated byWells Fargo & Company
$10.29
+4.7%
$30.00Overweight
S
SentinelOne
Target Lowered byPiper Sandler
Rob Owens
$47.89
-6.2%
$65.00 ➝ $55.00Neutral ➝ Neutral
S
SentinelOne
Target Lowered byDeutsche Bank Aktiengesellschaft
Patrick Colville
$47.89
-6.2%
$77.00 ➝ $63.00Buy ➝ Buy
S
SentinelOne
Target Lowered byWells Fargo & Company
Andrew Nowinski
$47.89
-6.2%
$80.00 ➝ $60.00Overweight ➝ Overweight
S
SentinelOne
Target Lowered byLoop Capital
Yun Kim
$47.89
-6.2%
$82.00 ➝ $65.00Buy
S
SentinelOne
Target Lowered byBank of America
$47.89
-6.2%
$77.00 ➝ $67.00Buy
S
SentinelOne
Target Lowered byUBS Group
$47.89
-6.2%
$79.00 ➝ $75.00Buy
S
SentinelOne
Initiated byNeedham & Company LLC
Alex Henderson
$47.89
-6.2%
$81.00Buy
SAN
Banco Santander
Downgraded byCredit Suisse Group
Pamela Zuluaga
$3.10
-2.5%
Outperform ➝ Neutral
SFIX
Stitch Fix
Target Lowered byTelsey Advisory Group
$19.53
-21.8%
$55.00 ➝ $40.00Outperform
SFIX
Stitch Fix
Downgraded byEvercore ISI
Mark Mahaney
$19.53
-21.8%
$68.00 ➝ $24.00Outperform ➝ In-Line
SFIX
Stitch Fix
Downgraded byKeyCorp
Edward Yruma
$19.53
-21.8%
Overweight ➝ Sector Weight
SFIX
Stitch Fix
Target Lowered byCanaccord Genuity
Maria Ripps
$19.53
-21.8%
$50.00 ➝ $38.00Buy ➝ Buy
SFIX
Stitch Fix
Target Lowered byBarclays
Ross Sandler
$19.53
-21.8%
$37.00 ➝ $22.00Equal Weight ➝ Equal Weight
SFIX
Stitch Fix
Target Lowered byWells Fargo & Company
$19.53
-21.8%
$35.00 ➝ $14.00Underweight
SFIX
Stitch Fix
Target Lowered byWedbush
T. Nikic
$19.53
-21.8%
$45.00 ➝ $21.00Neutral ➝ Neutral
SFIX
Stitch Fix
Target Lowered byPiper Sandler
Erinn Murphy
$19.53
-21.8%
$46.00 ➝ $22.00Neutral ➝ Neutral
SFIX
Stitch Fix
Target Lowered byRobert W. Baird
Mark Altschwager
$19.53
-21.8%
$52.00 ➝ $25.00Neutral ➝ Neutral
SFIX
Stitch Fix
Target Lowered byBMO Capital Markets
Simeon Siegel
$19.53
-21.8%
$40.00 ➝ $25.00Market Perform ➝ Market Perform
SHIP
Seanergy Maritime
Reiterated byHC Wainwright
Magnus Fyhr
$1.08
-3.2%
$2.00Buy
SIMO
Silicon Motion Technology
Target Raised byB. Riley
$89.26
+1.5%
$113.00 ➝ $125.00Buy
SIVB
SVB Financial Group
Upgraded byWells Fargo & Company
$709.62
-1.0%
$715.00 ➝ $900.00Equal Weight ➝ Overweight
SJW
SJW Group
Target Raised byBarclays
Eric Beaumont
$69.12
-0.5%
$70.00 ➝ $75.00Equal Weight
SR
Spire
Target Lowered byMizuho
Gabe Moreen
$63.96
+1.5%
$69.00 ➝ $68.00Buy ➝ Buy
STM
STMicroelectronics
Downgraded byMorgan Stanley
$48.88
-2.5%
Overweight ➝ Equal Weight
SYNA
Synaptics
Target Raised byCowen
$288.77
-1.4%
$250.00 ➝ $310.00Outperform ➝ Outperform
TASK
TaskUs
Target Lowered byRoyal Bank of Canada
Daniel Perlin
$44.62
+6.0%
$69.00 ➝ $62.00Outperform ➝ Outperform
TMUS
T-Mobile US
Target Set bySanford C. Bernstein
Supino Peter
$114.78
-2.0%
$175.00
TRUP
Trupanion
Target Raised byPiper Sandler
John Barnidge
$154.55
-0.6%
$126.00 ➝ $183.00Overweight ➝ Overweight
TSEM
Tower Semiconductor
Target Raised byJefferies Financial Group
$38.43
-0.2%
$42.00 ➝ $46.00Buy ➝ Buy
TSLA
Tesla
Target Raised byNew Street Research
Pierre Ferragu
$1,063.39
+1.1%
$1,298.00 ➝ $1,580.00Buy ➝ Buy
TTCF
Tattooed Chef
Initiated byCowen
$16.40
+3.4%
$24.00Outperform
UMC
United Microelectronics
Downgraded byJPMorgan Chase & Co.
$11.70
-6.7%
Overweight ➝ Neutral
VIR
Vir Biotechnology
Reiterated byHC Wainwright
Patrick Trucchio
$42.79
-0.4%
$199.00Buy
VZIO
VIZIO
Initiated byCraig Hallum
$20.50
+5.1%
$28.00Buy
WB
Weibo
Target Lowered byThe Goldman Sachs Group
Piyush Mubayi
$32.98
-1.5%
$54.00 ➝ $44.50Neutral ➝ Neutral
WEJO
Wejo Group
Initiated byRobert W. Baird
$6.79
+16.9%
$12.00Outperform
WLL
Whiting Petroleum
Target Raised byCowen
$69.66
+0.6%
$80.00 ➝ $85.00Outperform ➝ Outperform
WTRG
Essential Utilities
Upgraded byBarclays
$50.73
+1.1%
$50.00 ➝ $56.00Equal Weight ➝ Overweight
XOM
Exxon Mobil
Target Raised byBarclays
Wai Jeanine
$62.46
+0.3%
$71.00 ➝ $73.00Overweight ➝ Overweight
XOS
XOS
Initiated byBank of America
$3.65
-5.2%
$3.00Underperform

Always Get the Latest Analyst Ratings and Price Targets: Stay ahead of the market with MarketBeat.com's daily email update that provides a summary of analysts' upgrades, downgrades and new coverage. Click here to register.

This page was last refreshed on Wednesday at 02:55 PM ET.

Terms like “Buy”, “Sell”, and “Hold” are synonymous with financial analysts’ reports, yet very few people have a clear understanding of what they are and the best way to use them for value generation in the stock market.  The terms are usually the result of thorough investigations carried out by brokerage firms and analysts as they look to make it easy for investors to make informed decisions about investments.

Market ratings are a multi-level recommendation system based on facts and the opinion of a financial analyst. The fact that there is a multitude of firms issuing differing ratings and a lack of a standard terminology explains why it is essential to understand what the ratings are all about and their meaning before using them for investment decisions.

What Are Stock Ratings

A stock rating refers to an evaluation of a stock’s expected performance in a given time period.  The rating is usually accompanied by a target price that analysts or brokerage firm issue with the aim of helping clients understand what is the fair price of a stock compared to its market value.

A stock rating will often come with a price target that shows what analysts believe is the fair value for the stock. Whenever the price target exceeds the market value, then it implies analysts believe the stock is a buy.  If the market price for the stock exceeds the target price, analysts or brokerage firms would say that the stock is a sell.

Understanding Analysts Stock Ratings

Analysts' ratings range from a simple buy, sell or hold to an equal-weight, overweight or outperform. Many brokerage firms rate a stock on a scale of one to five stars, with five being the highest rating. The ratings are assigned depending on the kind of earnings the company has reported or what it is expected to report as well as on valuations and stock price.

Corporate governance, as well as the scalability of a company’s business, are also taken into consideration when rating stocks. Analysts also pay close attention to a company’s competitive edge in the industry, as it is known to affect performance most of the time.

Market conditions also play into how stocks are rated. For example, in a bull market, analysts are usually swayed to keep favorable ratings for a long time while upgrading share price target. Conversely, during a bear market, analysts may resort to downgrading stock ratings.

While ratings may seem straightforward to an investing newcomer, in reality, a rating from one brokerage firm may mean an entirely different thing in another firm. For example, an outperform rating issued by one firm may mean a buy for another firm, while a sell may mean under­perform.

When it comes to integrating analysts' ratings, it is important first to review a firm’s rating scale to get a full understanding of what it is all about and what it means.  For example, a stock with the potential of delivering a 15% upside in price may be rated as a buy while one with a 5% upside rated as a hold.

Types of Stock Ratings

Buy Stock Rating: A buy rating indicates that a stock is worth buying at a given market price as it is destined to rise. Some firms use ‘strong buy’ to indicate how confident they are that a stock will climb higher given the strong fundamentals backing a move on the upside.

Sell Stock Rating: Sell recommendations are normally issued whenever analysts believe a stock is overvalued or fundamentals do not add up to support any movements on the upside. Some firms use ‘strong sell' to indicate that it is time to liquidate the security.

Hold Stock Rating: A security hit with a hold rating is most of the time expected to perform at the same pace as other stocks in the sector.

Underperform:  Analysts issue an underperform rating whenever they feel a stock is likely to fair worse than the overall market.  The rating is most of the time expressed as a moderate sell, warning investors who are long that a stock is losing upside momentum.

Outperform Stock Rating:  An outperform rating indicates that a stock is likely to perform much better than the market when it comes to returns. Also known as moderate buy or overweight, the rating hints at an uptrend gaining momentum.

It is important to read each rating definition to have a clear understanding of what it means given that ratings from different firms do differ a great deal.  Some ratings do offer specific recommendations while others are usually general in nature. One firm may say it expects a stock to appreciate by between 10 and 20% while another firm may say it expects a stock to appreciate over the next 12 months.

Brokerage Firm

Buy

Strong Buy

Out­perform

Hold

Sell

Under­perform

BB&T Capital Markets

 

Esti­mated return of greater than or equal to 25%

 

Esti­mated Total Return  greater than or equal to 0%

 

Esti­mated Total Return of Less than 0%

Blay­lock Partners

Stock Expected to out­perform market indexes by 20%

 

 

Expects stock to track recog­nized market indexes

Expects stock  to under­perform the overall market by 20%

 

Barring­ton Research

 

Expected to out­perform the market over the next 6 months

Expected to out­perform the market over the next 12 months

 

Expected to significantly under­perform the market as a result of deterior­ating fundamentals

 

Brean Murray & Co

Stock expected to out­perform the market over the next 12 months with moderate risks to funda­mentals

Stock expected to out­perform the market over the next 12 months it minimal risks to funda­mentals

 

Expected to perform in line with the market over the next 6-12 months

Exacted to under­perform the market over the next 6-12 months with high risk to funda­mentals

 

Deutsche Bank  Securities

Stock poised to outperform the market by 10% or more over the next 12 months

Repre­sents firm best picks with a high degree of confi­dence. Stock expected to out­perform the market

 

 

 

Stock expected to under­perform the market by 10% over the next 12 months

Jefferies & Co

A stock is expected to appre­ciate by 20% or more. The total return should exceed the industry average

 

 

Stock expected to change plus or minus 10%. The total return should be  in line with the industry's average

Stock expected to decrease by more than 10%

 

 

Why Stock Ratings Matter

While investors have a love-hate relationship with stock analysts’ ratings, they still matter a lot, as they convey how professionals feel about a given security. They will always stand out in part because they are the result of reasoned and objective analysis of experienced professionals.

Analysts and brokerage firms spend a good amount of time and effort to analyze companies in a bid to come up with accurate stock ratings that investors can rely on for making informed investment decisions. Investors should always remember that analysts do their best with stock ratings to find good investments for their clients in order to secure their reputation in the industry as well as the commissions they earn for such pieces of information.

Legitimate ratings will always be valuable pieces of information that investors can rely on to beat the market and in the process generate substantial returns. However, while it is essential to always be on the lookout for analysts’ ratings, it does not mean that investors should always adjust their position based on such reports.

Such reports should only be used to complement individual research work prior to making an investment decision.  Stock analysts’ reports should thus be used to find a company with a durable competitive advantage.

Stock ratings are a great place to start when selecting stocks

Stock analysts' rating pages are a great place to start when looking for potential stocks to invest in. Such recommendations go a long way in providing insight on stocks that are performing and likely to perform even better going forward.

Reputable analysts and brokerage firms issue recommendations upon carrying out extensive research of a company’s operations and performance. The analysis also takes into consideration some of the market conditions that are likely to affect a company in the long run.

By going through such research pages, one can get an insight on where to start when carrying out due diligence on the stocks to invest in. In addition, such reports may provide common investment strategies that one can deploy on a given stock to be able to generate some returns.

Before making an investment decision, it is essential to consider analysts' ratings in addition to other metrics. Analyst’s ratings are never 100% accurate, which means they cannot be taken at face value.  That said, it is important to analyze everything from P/E ratio to earnings per share as well as dividends, risk, and growth of financial strength.

The key to success is analyzing below the surface when it comes to stock analysts' ratings. Never assume that just because a stock is rated a buy, it means it can be bought at any time at any price.

Bottom Line

Analysts’ recommendations in the form of stock ratings are the foundation of equity research reports that should always be used in combination with other personal research work for investment decisions. Buy, sell and hold recommendations should never be put to use without first understanding a firm’s entire scale of ratings.

It is also important for investors to note that analysts and brokerage firms also have agendas. While an analyst's obligation should be to retail shareholders, in reality, that is not always the case.

Some analysts are employed by institutions that own stakes in companies they have already initiated coverage on. Large financial firms, as well as hedge funds and securities, do benefit from certain analyst ratings. When such sums are at stake, it is common for these analysts to issue ratings that are favorable to their holdings, which may not be an accurate reflection of the market conditions.

However, that does not mean that an analyst’s ratings are useless. Analyst's stock research reports do contain vital information. Such information when complemented with other information found by carrying out due diligence could go a long way in helping one make a profitable investment decision.  Stock ratings should always be used as a source of data that complements one's research rather than completes it.

 



Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.